Mass spectrometric investigations into the brain delivery of abacavir, stavudine and didanosine in a rodent model

References

• Ahluwalia G, Cooney DA, Mitsuya H, et al. (1987). Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol 36:3797–800.
   PubMed Web of Science ®Google Scholar
• Antinori A, Perno CF, Giancola ML, et al. (2005). Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis 41:1787–93.
   PubMed Web of Science ®Google Scholar
• Baijnath S, Moodley C, Ngcobo B, et al. (2018). Clofazimine protects against Mycobacterium tuberculosis dissemination in the central nervous system following aerosol challenge in a murine model. Int J Antimicrob Agents 51:77–81.
   PubMed Web of Science ®Google Scholar
• Best BM, Letendre SL, Koopmans P, et al. (2012). Low CSF concentrations of the nucleotide HIV reverse transcriptase inhibitor, Tenofovir. Jaids 59:376–81.
   Google Scholar
• Boffito M, Back DJ, Blaschke TF, et al. (2003). Protein binding in antiretroviral therapies. AIDS Res Hum Retrovir 19:825–35.
   PubMed Web of Science ®Google Scholar
• Brady KA, Boston RC, Aldrich JL, MacGregor RR. (2005). Stavudine entry into cerebrospinal fluid after single and multiple doses in patients infected with human immunodeficiency virus. Pharmacother J Hum Pharmacol Drug Ther 25:10–7.
   Google Scholar
• Burger DM, Kraayeveld CL, Meenhorst PL, et al. (1995). Study on didanosine concentrations in cerebrospinal fluid. Pharm World Sci 17:218–21.
   PubMedGoogle Scholar
• Capparelli EV, Letendre SL, Ellis RJ, et al. (2005). Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob Agents Chemother 49:2504–6.
   PubMed Web of Science ®Google Scholar
• Chiang M-C, Dutton RA, Hayashi KM, et al. (2007). 3D pattern of brain atrophy in HIV/AIDS visualized using tensor-based morphometry. NeuroImage 34:44–60.
   PubMed Web of Science ®Google Scholar
• Clifford DB, Ances BM. (2013). HIV-associated neurocognitive disorder (HAND). Lancet Infect Dis 13:976–86.
   PubMed Web of Science ®Google Scholar
• Cobo J, Ruiz M, Figueroa M, et al. (1996). Retinal toxicity associated with didanosine in HIV-infected adults. AIDS (London, England) 10:1297.
   PubMed Web of Science ®Google Scholar
• Crimmins MT, King BW. (1996). An efficient asymmetric approach to carbocyclic nucleosides: asymmetric synthesis of 1592U89, a potent inhibitor of HIV reverse transcriptase. J Org Chem 61:4192–3.
   PubMed Web of Science ®Google Scholar
• Dando SJ, Mackay-Sim A, Norton R, et al. (2014). Pathogens penetrating the central nervous system: infection pathways and the cellular and molecular mechanisms of invasion. Clin Microbiol Rev 27:691–726.
   PubMed Web of Science ®Google Scholar
• DeJesus E, Herrera G, Teofilo E, et al. (2004). Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 39:1038–46.
   PubMed Web of Science ®Google Scholar
• Demeule M, Regina A, Jodoin J, et al. (2002). Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul Pharmacol 38:339–48.
   PubMed Web of Science ®Google Scholar
• Dudley MN, Graham KK, Kaul S, et al. (1992). Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J Infect Dis 166:480–5.
   PubMed Web of Science ®Google Scholar
• Ene L, Duiculescu D, Ruta SM. (2011). How much do antiretroviral drugs penetrate into the central nervous system? J Med Life 4:432–9.
   PubMedGoogle Scholar
• Engelhardt B, Sorokin L. (2009). The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol 31:497–511.
   PubMed Web of Science ®Google Scholar
• Foudraine NA, Hoetelmans RMW, Lange JMA, et al. (1998). Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 351:1547–51.
   PubMed Web of Science ®Google Scholar
• Gabrielian A, MacCumber MM, Kukuyev A, et al. (2013). Didanosine-associated retinal toxicity in adults infected with human immunodeficiency virus. JAMA Ophthalmol 131:255–9.
   PubMed Web of Science ®Google Scholar
• Genis P, Jett M, Bernton EW, et al. (1992). Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: implications for the neuropathogenesis of HIV disease. J Exp Med 176:1703–18.
   PubMed Web of Science ®Google Scholar
• Gisslén M, Norkrans G, Svennerholm B, Hagberg L. (1997). The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. J Infect Dis 175:434–7.
   PubMed Web of Science ®Google Scholar
• Haworth SJ, Christofalo B, Anderson RD, Dunkle LM. (1998). A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults. J Acquir Immune Defic Syndr Hum Retrovirol 17:235–8.
   PubMedGoogle Scholar
• Heaton RK, Franklin DR, Ellis RJ, et al. (2011). HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17:3–16.
   PubMed Web of Science ®Google Scholar
• HIV-Statistics SA, (2018). Statistical release P0302. Available at: www.statssa.gov.za [last accessed 11 Jan 2018].
   Google Scholar
• Hughes W, McDowell JA, Shenep J, et al. (1999). Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children. Antimicrob Agents Chemother 43:609–15.
   PubMed Web of Science ®Google Scholar
• Källback P, Nilsson A, Shariatgorji M, Andrén PE. (2016). msIQuant-quantitation software for mass spectrometry imaging enabling fast access, visualization, and analysis of large data sets. Anal Chem 88:4346–53.
   PubMed Web of Science ®Google Scholar
• Kanamitsu K, Kusuhara H, Schuetz JD, et al. (2017). Investigation of the importance of multidrug resistance-associated protein 4 (Mrp4/Abcc4) in the active efflux of anionic drugs across the blood-brain barrier. J Pharm Sci 106:2566–75.
   PubMed Web of Science ®Google Scholar
• Kim RB, Fromm MF, Wandel C, et al. (1998). The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289–94.
   PubMed Web of Science ®Google Scholar
• Kiyomi T, L WS, E GD, et al. (1996). Localization of HIV‐1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. Ann Neurol 39:705–11.
   PubMed Web of Science ®Google Scholar
• Kline MW, Dunkle LM, Church JA, et al. (1995). A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics 96:247–52.
   PubMed Web of Science ®Google Scholar
• Knupp CA, Brater DC, Relue J, Barbhaiya RH. (1993). Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus. J Clin Pharmacol 33:912–7.
   PubMed Web of Science ®Google Scholar
• Letendre S.. (2011). Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Topic Antivir Med 19:137–42.
   PubMedGoogle Scholar
• Luzzio FA, Menes ME. (1994). A facile route to pyrimidine-based nucleoside olefins: application to the synthesis of d4T (Stavudine). J Org Chem 59:7267–72.
   Web of Science ®Google Scholar
• McComsey GA, Re, Iii VL, O’Riordan M, et al. (2008). Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study. Clin Infect Dis 46:1290–6.
   PubMed Web of Science ®Google Scholar
• McDowell JA, Chittick GE, Ravitch JR, et al. (1999). Pharmacokinetics of [14C] abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob Agents Chemother 43:2855–61.
   PubMed Web of Science ®Google Scholar
• Mdanda S, Baijnath S, Shobo A, et al. (2017). Lansoprazole‐sulphide, pharmacokinetics of this promising anti‐tuberculous agent. Biomed Chromatogr 31:12.
   Web of Science ®Google Scholar
• Moyle GJ, Sabin CA, Cartledge J, et al. (2006). A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AID 20:2043–50.
   PubMed Web of Science ®Google Scholar
• Navia BA, Jordan BD, Price RW. (1986). The AIDS dementia complex: I. Clinical features. Ann Neurol 19:517–24.
   PubMed Web of Science ®Google Scholar
• Nguyen B-Y, Shay LE, Wyvill KM, et al. (1993). A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infection. J Infect Dis 168:810–7.
   PubMed Web of Science ®Google Scholar
• Ntshangase S, Shobo A, Kruger HG, et al. (2017). The downfall of TBA-354 – a possible explanation for its neurotoxicity via mass spectrometric imaging. Xenobiotica. 48:938–944.
   Google Scholar
• Pamreddy A, Baijnath S, Naicker T, et al. (2018). Bedaquiline has potential for targeting tuberculosis reservoirs in the central nervous system. RSC Adv. 8:11902–7.
   Web of Science ®Google Scholar
• Parkin NT, Hellmann NS, Whitcomb JM, et al. (2004). Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob Agents Chemother 48:437–43.
   PubMed Web of Science ®Google Scholar
• Podzamczer D, Ferrer E, Sanchez P, et al. (2007). Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J AIDS 44:139–47.
   PubMed Web of Science ®Google Scholar
• Power C, Selnes OA, Grim JA, McArthur JC. (1995). HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol 8:273–8.
   PubMed Web of Science ®Google Scholar
• Price RW, Spudich S. (2008). Antiretroviral therapy and central nervous system HIV-1 infection. J Infect Dis 197:S294–S306.
   PubMed Web of Science ®Google Scholar
• Raices RSL, Salvadori MC, Estrela R. d C E, et al. (2003). Determination of stavudine in human serum by on‐line solid‐phase extraction coupled to high‐performance liquid chromatography with electrospray ionization tandem mass spectrometry: application to a bioequivalence study. Rapid Commun Mass Spectrom 17:1611–8.
   PubMed Web of Science ®Google Scholar
• Sankatsing SUC, Beijnen JH, Schinkel AH, et al. (2004). P glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob Agents Chemother 48:1073.
   PubMed Web of Science ®Google Scholar
• Saylor D, Dickens AM, Sacktor N, et al. (2016). HIV-associated neurocognitive disorder-pathogenesis and prospects for treatment. Nature Reviews. Neurology 12:234–48.
   PubMed Web of Science ®Google Scholar
• Seelig A, Landwojtowicz E. (2000). Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur J Pharm Sci 12:31–40.
   PubMed Web of Science ®Google Scholar
• Shaik N, Giri N, Pan G, Elmquist WF. (2007). P-glycoprotein-Mediated Active Efflux of the Anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metab Dispos 35:2076.
   PubMed Web of Science ®Google Scholar
• Sharom FJ. (1997). The P-glycoprotein efflux pump: how does it transport drugs? J Membr Biol 160:161–75.
   PubMed Web of Science ®Google Scholar
• Silva MM. (2012). Neurologic complications of HIV in the HAART era: where are we? Braz J Infect Dis 16:373–8.
   PubMed Web of Science ®Google Scholar
• Teklezgi BG, Pamreddy A, Baijnath S, et al. (2019). Time-dependent regional brain distribution of methadone and naltrexone in the treatment of opioid addiction. Addict Biol 24:438–46.
   PubMed Web of Science ®Google Scholar
• Thompson PM, Dutton RA, Hayashi KM, et al. (2005). Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4(+) T lymphocyte decline. PNAS 102:15647–52.
   PubMed Web of Science ®Google Scholar
• Tisdale M, Kemp SD, Parry NR, Larder BA. (1993). Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 90:5653–6.
   PubMed Web of Science ®Google Scholar
• Venter WDF, Innes S, Cotton M. (2012). Low-dose stavudine trials: a public health piority for developing countries. South Afr J HIV Med 13:20.
   Google Scholar
• Woods SP, Moore DJ, Weber E, Grant I. (2009). Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev 19:152–68.
   PubMed Web of Science ®Google Scholar
• Wynn HE, Brundage RC, Fletcher CV. (2002). Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs 16:595–609.
   PubMed Web of Science ®Google Scholar
• Yilmaz A, Price RW, Gisslén M. (2012). Antiretroviral drug treatment of CNS HIV-1 infection. J Antimicrob Chemother 67:299–311.
   PubMed Web of Science ®Google Scholar
• Yuen GJ, Weller S, Pakes GE. (2008). A review of the pharmacokinetics of abacavir. Clin Pharmacokinet 47:351–71.
   PubMed Web of Science ®Google Scholar